Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

14.11.2023 - JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial ...

Related Keywords

United States ,Israel ,United Kingdom ,American ,Miranda Toledano ,Health Inc ,Mineral Research ,Pamerican Society For Bone ,Society Of Bone ,Nasdaq ,Drug Administration ,Executive Officer ,Peptide Programs ,First Oral ,Daily Osteoanabolic Tablets ,Total Hip Bone Mineral Density ,American Society ,Regulatory Endpoint ,Osteoanabolic Tablets ,Treat Intense Sport ,Military Stress ,Annual Society ,Peptide Replacement Therapy Tablets ,Short Bowel ,Glucagon Agonist ,Peptide Tablets ,Threemonths Ended September ,Centera Bio ,Private Securities Litigation Reform Act ,Statements Regarding Forward Looking ,Financial Condition ,Quarterly Reports ,Current Reports ,Miranda Toledano Chief Executive Officer Email ,Entera Bio Chart ,Ntera Bio Kurs ,Ntera Bio Aktie ,